Advertisement Genta receives Nasdaq noncompliance notice - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Genta receives Nasdaq noncompliance notice

Genta has been notified by the Nasdaq that it no longer complies with the minimum closing bid price.

The company has until June 16, 2008 to regain compliance, which requires a closing bid price of the company’s common stock at or above $1 per share for a minimum of 10 consecutive business days. In the event the company does not regain compliance within this period, the company may appeal a delisting determination by the Nasdaq Listing Qualifications Panel, and the company’s securities would remain listed pending the panel’s decision.